By Mariam Sunny and Siddhi Mahatole (Reuters) -French drugmaker Sanofi said the U.S. Food and Drug Administration has ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...

Sanofi is harnessing the power of pop music to boost awareness of the experience of living with Type 1 diabetes. | Sanofi is ...

Sanofi and Vietnam Vaccine JSC, or VNVC, on Tuesday launched a vaccine manufacturing facility in Vietnam, aimed at producing ...

Sanofi and Stagecoach Performing Arts are excited to introduce a unique partnership. Selected through a UK-wide audition ...

Self-regulatory body the PMCPA ruled the company brought discredit on the pharma industry by giving 21 tickets to the games, ...

Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.

Sanofi’s 11 months watching over Vigil Neuroscience have led to a $470 million buyout. | Sanofi’s 11 months watching over ...

Sanofi (NASDAQ:SNY), in partnership with Vietnam Vaccine JSC (VNVC), officially launched a state-of-the-art vaccine ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...